Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05103332 · ClinicalTrials.gov registry record · Phase 2
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)
A Phase 2 study, sponsored by Alnylam Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 663
- Enrollment target
NCT05103332 is a Phase 2 study that has completed, run by Alnylam Pharmaceuticals. The registered enrollment target is 663 participants.
The verdict
NCT05103332, a Phase 2 study, has completed, sponsored by Alnylam Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 663 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of zilebesiran on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of zilebesiran as add-on therapy.
Interventions
- DRUG Placebo
- DRUG Amlodipine
- DRUG Zilebesiran
- DRUG Olmesartan
- DRUG Indapamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 663 participants |
| Start Date | 2021-11-05 |
| Est. Completion | 2024-09-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05103332
The ClinicalTrials.gov registry entry for NCT05103332 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 663 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alnylam Pharmaceuticals, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT05103332 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05103332 about?
NCT05103332 is a clinical study titled "Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)". The purpose of this study is to evaluate the effect of zilebesiran on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of zilebesiran as add-on therapy.
What is the current status of trial NCT05103332?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 663 participants. The study started on 2021-11-05. Estimated completion is 2024-09-13.
What interventions are being tested in trial NCT05103332?
The interventions under investigation include: Placebo (DRUG), Amlodipine (DRUG), Zilebesiran (DRUG), Olmesartan (DRUG), Indapamide (DRUG).
Who is sponsoring clinical trial NCT05103332?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.